RESUMO
OBJECTIVE: The aim: In this study, we try to investigate whether evolocumab or its combination with atorvastatin has potent effect on lipid profile? PATIENTS AND METHODS: Materials and methods: Forty local domestic male rabbits were included in this study, and categorized into four group, two untreated group (nohypercholostermic and untreated hypercholostermic) and treated groups (evolocumab treated group at dose 6.1mg/kg/2Wk and atorvastatin treated group at dose 3.5 mg/kg/day),the blood samples were analyzed at base line and after 5week and at the end of the study after 10 weeks for lipid profile by standard enzymatic methods. RESULTS: Results: The serum levels of total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C),were increased after 10 weeks of administration of the atherogenic diet significantly (p<0.05) as compared with other groups (group I: 61.19 ± 14, group ΙΙ: 1301 ± 443, group ΙΙΙ 41.01 ± 5.81: 280 ± 50, group ΙV: 190 ± 38 group Ι: 46 ± 15.0, group ΙΙ: 256.0 ± 24.0, group ΙΙΙ: 101.0±28, group ΙV: 48.18 ± 15.27, group Ι: 29±14.50, group ΙΙ: 929±251.0, group ΙΙΙ: 283.0±36, group ΙV: 209.0±33mg/dl) respectively while the levels of high-density lipoprotein cholesterol (HDL-C) decrease (18.0±4.1 to 15.0±3.0mg/dl). Compared with evolocumab monotherapy, combination of evolocumab and atorvastatin reduce serum level of total cholesterol, triglyceride and low density lipoprotein more than that of evolocumab. CONCLUSION: Conclusions: Preproteins convert as esubtilisin/kexin type 9 inhibitor regulates the serum levels of lipid and cholesterol by lowering LDL-C, and the results also indicate that combination of evolocumab and atorvastatin are more potent in lowering the lipid profile and then reduce progression of atherosclerosis than evolocumab alone in rabbits suggesting that this combination might be beneficial for treatment of atherosclerosis.